FDA finds drugmaker using filthy kitchen utensils to produce cervical biopsy solution

A warning letter has been sent by the FDA to BioDiagnostic International for its plant in Brea, California. (Al Drago/CQ Roll Call via Getty Images)

A California drugmaker has been eviscerated in an FDA warning letter after inspectors found it using “kitchen cooking pots and household power tools” to manufacture a drug for vaginal use to stop bleeding after cervical biopsies.

The FDA says the drug was produced under filthy conditions by BioDiagnostic International at its plant in Brea, California.

BioDiagnostic has recalled all of its products, which are distributed by MedGyn Products, of Addison, Illinois, but the FDA has warned healthcare professionals to avoid them. The agency said there have not been any reports so far of adverse events.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

The FDA during its inspection in January noted the company’s manufacturing area was open to the outdoors and included an area for employees to prepare their own food.

“During the inspection, our investigator observed filthy conditions in your facility, including dirty equipment and utensils covered with unknown residue. ...The insanitary conditions observed at your facility failed to protect drug products from contamination with filth.”

The FDA noted the plant was not routinely testing the solution for microbial contamination. While the company offered explanations and said it intended to make improvements such as hiring a “professional cleaning crew,” the FDA was not impressed. It suggested the drugmaker hire a professional consultant if it intended to continue to produce drugs at the plant.

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.